Canopy Growth (CGC, $43.87) fiscal Q3 revenue beats analysts’ expectations
On Tuesday, Canadian cannabis company Canopy Growth reported fiscal third-quarter revenue that surpassed analysts’ expectations. However, the company incurred a loss during the period.
The company’s revenue grew +23% year-over-year to a record-setting $152.5 million in the three months ending Dec. 31, 2020.
Canopy Growth’s fiscal third-quarter net loss came in at -C$829 million (-US$651.1 million), from $720 million in the year-ago quarter.
Adjusted earnings (loss) before interest, taxes, depreciation and amortization for the quarter were -C$68 million vs. - C$97 million a year ago.
Analysts polled by Bloomberg expected revenue of $148.9 million and an adjusted EBITDA loss of -$71.1 million.
Canopy expects to generate positive adjusted EBITDA during the second half of 2022, and 20 per cent adjusted EBITDA margin for the full year 2024. It projects positive operating cash flow for the full year of 2023, and positive free cash flow for the full year of 2024. The forecasts are based on Canopy’s cost savings strategy, and expectations for compound annual net revenue growth of 40 to 50 per cent between 2022 and 2024.
"We are executing against our cost savings program, with several initiatives already completed and more underway to build a leaner and more agile business," chief financial officer Mike Lee said.
There is a broader rally in Canadian cannabis shares, fueled by hopes for a policy shift in the U.S that would remove pot from the country’s list of Schedule 1 drugs.
Momentum Indicator for CGC turns negative, indicating new downward trend
CGC saw its Momentum Indicator move below the 0 level on February 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In of the 79 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CGC turned negative on February 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
CGC moved below its 50-day moving average on January 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGC crossed bearishly below the 50-day moving average on January 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CGC entered a downward trend on February 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.752) is normal, around the industry mean (25.258). P/E Ratio (0.000) is within average values for comparable stocks, (77.554). CGC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.060). CGC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (1.304) is also within normal values, averaging (112.132).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of medical marijuana
Industry PharmaceuticalsGeneric
Advertisement